Elevated serum interferon-γ-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 4, 2005, Pages 2357-2363

  Rotondi, Mario ^a   Falorni, Alberto ^b   De Bellis, Annamaria ^a   Laureti, Stefano ^b   Ferruzzi, Pietro ^c   Romagnani, Paola ^c   Buonamano, Andrea ^c   Lazzeri, Elena ^c   Crescioli, Clara ^c   Mannelli, Massimo ^c   Santeusanio, Fausto ^b   Bellastella, Antonio ^a   Serio, Mario ^c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; STEROID 21 MONOOXYGENASE; TUMOR NECROSIS FACTOR ALPHA;

ADDISON DISEASE; ADRENAL GLAND; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ZONA FASCICULATA;

ADDISON DISEASE; ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; AUTOIMMUNITY; CELLS, CULTURED; CHEMOKINES, CXC; CYTOKINES; HUMANS; HYDROCORTISONE; INTERFERON TYPE II;

EID: 20244368199     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1062     Document Type: Article

References (38)

1. Laureti S, Vecchi L, Santeusanio F, Falorni A 1999 Is the prevalence of Addison's disease underestimated? J Clin Endocrinol Metab 84:1762
2. Falorni A, Laureti S, De Bellis A, Zanchetta R, Tiberti C, Arnaldi G, Bini V, Beck-Peccoz P, Bizzarro A, Dotta F, Mantero F, Bellastella A, Betterle C, Santeusanio F, SIE Addison Study Group 2004 Italian Addison Network Study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J Clin Endocrinol Metab 89:1598-1604
3. Jacobson DL, Gange SJ, Rose NR, Graham NMH 1997 Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84:223-243
4. Ten S, New M, Maclaren N 2001 Clinical review 130: Addison's disease. J Clin Endocrinol Metab 86:2909-2922
5. Betterle C, Dal Pra C, Mantero F, Zanchetta R 2002 Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 23:327-364
6. Peterson P, Uibo R, Krohn KJ 2000 Adrenal autoimmunity: results and developments. Trends Endocrinol Metab 11:285-290
7. Wardle CA, Weetman AP, Mitchell R, Peers N, Robertson WR 1993 Adrenocorticotropic hormone receptor-blocking immunoglobulins in serum from patients with Addison's disease: a reexamination. J Clin Endocrinol Metab 77:750-753
8. Myhre AG, Undlien DE, Lovas K, Uhlving S, Nedrebo BG, Fougner KJ, Trovik T, Sorheim JI, Husebye ES 2002 Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab 87:618-623
9. Volpé R 1981 Autoimmune diseases of the adrenals, gonads, and parathyroids: autoimmune polyendocrine disease. In: Volpé R, ed. Autoimmunity in endocrine system. Berlin: Springer-Verlag; 149-175
10. Fujii Y, Kato N, Kito J, Asai J, Yokochi T 1992 Experimental autoimmune adrenalitis: a murine model for Addison's disease. Autoimmunity 12:47-52
11. Freeman M, Weetman AP 1992 T and B cell reactivity to adrenal antigens in autoimmune Addison's disease. Clin Exp Immunol 88:275-279
12. Zlotnik A, Yoshle O 2000 Chemokines: a new classification system and their role in immunity. Immunity 12:121-127
13. Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Stricter RM 1997 The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukocyte Biol 62:554-562
14. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A 2001 Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56
15. + lymphocytes. J Clin Endocrinol Metab 86:5008-5016
16. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M 2002 Expression of IP-10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of subjects with recent onset Graves' disease. Am J Pathol 161:195-206
17. Antonelli A, Rotondi M, Fallahi P, Romagnani, P, Ferrari, SM, Buonamano A, Ferrannini E, Serio M 2004 High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 89:5496-5499
18. Shimada A, Morimoto J, Kodama K, Suzuki R, Oikawa Y, Funae O, Kasuga A, Saruta T, Narumi S 2001 Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 24:510-515
19. Nicoletti F, Conget I, Di Mauro M, Di Marco R, Mazzarino MC, Bendtzen K, Messina A, Gomis R 2002 Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 45:1107-1110
20. Rotondi M, Lazzeri E, Romagnani P, Serio M 2003 Role for interferon-γ inducile chemokines in endocrine autoimmunity: an expanding field. J Endocrinol Invest 26:177-180
21. Gonzalez-Hernandez JA, Bornstein SR, Ehrhart-Bornstein M 1994 Macrophages within the human adrenal gland. Morphological data for a possible local immune-neuroendocrine interaction. Cell Tissue Res 278:201-205
22. Bornstein SR, Rutkowski H, Vrezas I 2004 Cytokines and steroidogenesis. Mol Cell Endocrinol 215:135-141
23. Schteingart DE, Giordano TJ, Benitez RS, Burdick MD, Starkman MN, Arenberg DA, Strieter RM 2001 Overexpression of CXC chemokines by an adrenocortical carcinoma: a novel clinical syndrome. J Clin Endocrinol Metab 86:3968-3974
24. De Bellis A, Bizzarro A, Rossi R, Paglionico VA, Criscuolo T, Lombardi G, Bellastella A 1993 Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J Clin Endocrinol Metab 76:1002-1007
25. Laureti S, De Bellis A, Muccitelli VI, Calcinaro F, Bizzarro A, Rossi R, Bellastella A, Santeusanio F, Falotni A 1998 Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. J Clin Endocrinol Metab 83:3507-3511
26. Laureti S, Arvat E, Candeloro P, Di Vito L, Ghigo E, Santeusanio F, Falorni A 2000 Low dose (1 microg) ACTH test in the evaluation of adrenal dysfunction in pre-clinical Addison's disease. Clin Endocrinol (Oxf) 53:107-115
27. Munari-Silem Y, Lebrethon MC, Morand I, Rousset B, Saez JM 1995 Gap junction-mediated cell-to-cell communication in bovine and human adrenal cells. A process whereby cells increase their responsiveness to physiological corticotropin concentrations. J Clin Invest 95:1429-1439
28. Luciani P, Ferruzzi P, Arnaldi G, Crescioli C, Benvenuti S, Nesi G, Valeri A, Greeve I, Serio M, Mannelli M, Peri A 2004 Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. J Clin Endocrinol Metab 89:1332-1339
29. Narumi S, Takeuchi T, Kobayashi Y, Konishi K 2000 Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 12:1561-1565
30. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V 2001 Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 115:192-198
31. Nishioji K, Okanoue T, Itoh Y, Narumi S, Sakamoto M, Nakamura H, Morita A, Kashima K 2001 Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 123:271-279
32. Rotondi M, Romagnani P, Brozzetti A, Santeusanio F, Serio M, Falorni A 2003 To: Nicoletti F, Conget L, Di Mauro M et al (2002). Serum concentrations of the interferon-α-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 46:1020-1021
33. Gambelunghe G, Forini F, Laureti S, Murdolo G, Toraldo G, Santeusanio F, Brunetti P, Sanjeevi CB, Falorni A 2000 Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol (Oxf) 52:565-573
34. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP 2003 Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf) 59:207-213
35. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE 1993 Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119:1198-1208
36. Karin M 1998 New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 93:487-490
37. Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, Frucht DM, Chrousos GP, O'Shea JJ 2000 Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol 164:1768-1774
38. Hu X, Li WP, Meng C, Ivashkiv LB 2003 Inhibition of IFN-γ signaling by glucocorticoids. J Immunol 170:4833-4839